XRP2 Stock Chart & Stats
€11.40
-€0.50(-5.00%)
At close: 4:00 PM EDT
€11.40
-€0.50(-5.00%)
Day’s Range― - ―
52-Week Range€3.40 - €17.60
Previous CloseN/A
Volume0.00
Average Volume (3M)506.00
Market Cap
€1.09B
Enterprise Value€446.72M
Total Cash (Recent Filing)€72.05M
Total Debt (Recent Filing)€112.00K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 17, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.81
Shares Outstanding62,154,087
10 Day Avg. Volume454
30 Day Avg. Volume506
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.54
Price to Sales (P/S)171.24
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.10Price Target Upside50.03% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.32
Revenue Forecast (FY)€392.50K
Bulls Say, Bears Say
Bulls Say
Phase 2 Pipeline ValidationThe strong randomized Phase 2 result provides meaningful clinical validation for divesiran and supports progression toward Phase 3. If replicated, the efficacy, infrequent dosing, symptom improvements, and favorable safety profile could create a differentiated treatment option in polycythemia vera.
Improved Funding CapacityA substantial capital raise should extend the company’s ability to fund clinical development and advance its siRNA pipeline without relying immediately on another financing. Greater liquidity can support execution through later-stage trials and strengthen negotiating flexibility with potential partners.
Low Financial LeverageMinimal debt limits interest obligations and refinancing exposure, giving the company a cleaner liability structure while it develops its pipeline. This financial flexibility can help management direct available capital toward research and clinical programs rather than servicing significant borrowings.
Bears Say
Revenue Collapse And Persistent LossesThe sharp revenue deterioration and continuing large losses show that the current business has not yet established a reliable commercial earnings base. Sustained negative margins can limit internally funded investment and leave future progress dependent on successful pipeline execution or new financing.
Sustained Cash BurnPersistent negative operating and free cash flow indicates that ongoing research and clinical activity consumes substantial cash. The worsening TTM burn increases dependence on equity raises or partnerships, making long-term execution more sensitive to access to external funding.
Negative Shareholders’ EquityNegative equity reflects the cumulative effect of losses and signals substantial value erosion in the existing capital structure. Unless profitability improves or capital is replenished, this condition can constrain financial resilience and reduce flexibility in funding the company’s development plans.
Silence Therapeutics News
XRP2 FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was €3.40 and its highest was €17.60 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is €1.09B.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 25 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Aug 10, 2026. The company reported -€0.08 earnings per share for the quarter, beating the consensus estimate of -€0.124 by €0.044.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 62,154,087 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -€0.08 in its last earnings report, beating expectations of -€0.124. Following the earnings report the stock price went up 42.424%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in DE:XRP2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Silence Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€17.10 (50.03% Upside)
€17.10 (50.03% Upside)
Blogger Sentiment
Neutral
DE:XRP2 Sentiment 50%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 90%
Bearish news 10%
Bearish news 10%
Technicals
SMA
Positive
20 days / 200 days
Momentum
165.81%
12-Months-Change
Fundamentals
Return on Equity
-106.94%
Trailing 12-Months
Asset Growth
-35.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Silence Therapeutics
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
XRP2 Stock 12 Month Forecast
Average Price Target
€17.10
▲(50.03% Upside)